FDA Partial Clinical Hold Halts Bright Minds' U.S. Phase 2 DEE Trial of BMB-101
DRUG sits 30% above its 52-week low of $18.9 on elevated volume (12× avg).
Summary
The FDA placed a partial clinical hold on Bright Minds' IND and Phase 2 protocol for BMB-101 in DEEs, citing mouse toxicity and insufficient pediatric data. The hold covers only the planned U.S. DEE trial; the company is awaiting the full hold letter within 30 days.
Key Events · Product Development and Regulatory · DRUG
-
FDA Partial Clinical Hold on DEE Program
The FDA placed a partial clinical hold on the IND for Developmental and Epileptic Encephalopathies and Protocol BMB-101-105, blocking the planned U.S. Phase 2 trial of BMB-101.
-
Reasons: Mouse Toxicity, Pediatric Data
The FDA cited identified toxicity in mice and inadequate pharmacokinetic and juvenile toxicity data to support the proposed pediatric enrollment.
-
Scope Limited to U.S. DEE Trial
The company believes the hold covers only the planned U.S. Phase 2 DEE trial and does not affect its other ongoing clinical trials.
-
Full Hold Letter Due Within 30 Days
The FDA said it would provide the full Partial Clinical Hold Letter within 30 days, including additional details, non-hold recommendations and study-design recommendations; Bright Minds intends to immediately request clarification.
Analysis · DRUG · Life Sciences
The FDA has placed a partial clinical hold on Bright Minds' IND and Protocol BMB-101-105, blocking the planned U.S. Phase 2 trial of BMB-101 in developmental and epileptic encephalopathies. The agency cited toxicity in mice plus inadequate pharmacokinetic and juvenile toxicity data to support pediatric enrollment — a serious setback for the lead epilepsy program. Bright Minds argues the mouse findings were incidental and not drug-related, but that is the company's own belief, not an FDA finding. The hold is scoped to the U.S. DEE trial and does not affect other ongoing trials, and the FDA will send its full hold letter within 30 days with recommendations. Until that letter arrives and the issues are resolved, the U.S. DEE path is stalled, with no assurance on timing or whether the hold will be lifted.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DRUG was trading at $24.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $542.3M. The 52-week trading range was $18.90 to $123.75. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.